# Patent

## Title
Method for synthesis of ciguatoxin CTX1B and compounds useful for the synthesis of ciguatoxin CTX1B

## Abstract

Disclosed is a method for total synthesis of CTX1B, which is developed for the synthesis of a ciguatoxin analogue such as CTX3C and enables the more efficient application of an established reaction to the total synthesis of CTC1B. More specifically, disclosed is a method for total synthesis of CTX1B comprising; an O.S-acetal formation for synthesizing a novel compound (3); a radical cyclization reaction for constructing a 9-membered ring formation reaction including a novel compound (6) through a novel compound (8) and yielding a compound (D); and a deprotection for yielding CTX1B. Also disclosed are novel compounds (1) to (8) which are particularly useful for synthesis of CTX1B and can be used for the synthesis of a ciguatoxin analogue.

## Background
FIELD OF THE INVENTION
The present invention relates to the establishment of a method for total synthesis of ciguatoxin CTX1B which is a homolog of ciguatoxin, further, relates to a provision of compounds useful to make possible an effective method for preparation of said total synthesis.
BACKGROUND OF THE INVENTION
Food-poisoning, ciguatera caused by poisoning of originally non-toxic fishes, widely occurs in coral reef islands region of subtropical and tropical regions, and more than 50,000 people suffer annually from ciguatera. Although the mortality is not so high, symptoms such as abnormal sensation, diarrhea, lassitude, arthralgia or itching last for several months under some circumstances. Ciguatoxins (CTX), which are isolated and the structure of which is decided as a main originated poison of ciguatera, are macromolecules characterized by fused 13 ether rings and their molecular length is approximately 3 nm, further more than 20 kinds of homolog are existing. Ciguatoxins are produced from dinoflagellate Gambierdiscus toxicus and accumulate in fishes by means of food chain. Since approximately 400 kinds of toxic fishes are normal from the view points of appearance, taste and odor, it is not safe to exploit fish sources of southern sea region. Therefore, the development of detective method of ciguatoxins by means of easy and high sensitive immunological measuring method of ciguatoxins is strongly expected.
Ciguatoxins bind specifically to voltage-sensitive Na+ channels (VSSC) of excitable membranes, activate it and generate toxicity, however, the activation mechanism of ciguatoxins at structural level is not made clear yet. Ciguatoxins exist in nature is very small and cultural production by the dinoflagellate is very slow, detail biological research and the preparation of anti-CTX antibody using natural product is virtually impossible. Under said circumstances, the quantitative supply of natural ciguatoxins by practical chemical synthesis is strongly desired.
Inventors of the present invention already proposed a total synthesis of CTX3C, which is one of main homolog of ciguatoxin (non patent document 1, Proc. Natl. Acad. Sci. U.S.A. 101, 1203-12018 (2004)). Further, the inventors developed a Sandwich immunoassay that can detect CTX3C easily (non patent document 2, J. Am. Chem. Soc. 125, 7608-7612 (2003)) and are now investigating to apply it to identification of a ciguatera fish. However, since CTX3C is mainly contained in a herbivorous fish, preparation of an antibody originated to other homolog is necessary for detection of ciguatoxin from a carnivorous fish.
CTX1B is the most typical ciguatoxin contained mainly in a carnivorous fish and has more complicated structure than CTX3C, and is known as the most historically important ciguatoxin whose structure is firstly decided in 1989. At the decision of structure, 0.3 mg of CTX3B isolated from 4000 kg of poisonous moray is used. However, since it was actually impossible to obtain practical amount of sample from nature, development of total synthesis of CTX1B is awaited for the actual use of CTX1B as a standard sample.
Generally, in total synthesis, if partial structure is different, development of a new synthesis route becomes necessary. However, for the purpose to synthesis many ciguatoxin homologs existing in nature in a unified fashion, the inventors have developed convergent total synthesis, which is characterized to be remarkably simple and more reliable compared with competitive methods. By said method, supply of over than several mg of CTX3C became possible up to this time. According to said concept, since there is possibility that carnivorous fishes accumulate ciguatoxin by higher concentration than herbivorous fishes because carnivorous fishes are locating at upper position of food chain than herbivorous fishes and is more dangerous as a ciguatera poisoned fish, the inventors of the present invention considered to develop a new effective total synthesis of CTX1B for the purpose of investigation of CTX1B.
At the development of a new effective total synthesis, the inventors of the present invention considered to utilize the reaction sequence which were already developed for synthesis of CTX3C. Namely, the inventors considered to apply the coupling of ABCDE ring segments with HIJKLM ring segments and subsequent construction of FG ring to CTX1B. However, since 7-members ring E-structure, and a side chain existing in A ring segments of CTX1B are structurally different from CTX3C, direct application of methodology used in CTX3C was impossible. Therefore, the inventors planned to develop a higher yielding process from a view point of effective preparation of the aimed compound.
(1) At the formation of 7-members ring of compound D at radical ring forming reaction, preparation process of CTX3C can not be used. Therefore, the inventors designed compound 5 that has pentafluoroacrylate instead of conventionally used methylacrylate and yield of ring forming reaction is remarkably improved.
(2) At deprotection of naphthylmethyl (NAP) group, side chain of A ring segment is very unstable to acid and compound E acetal intermediate is formed at conventional acid hydrolysis of acetal. Therefore, various investigations for condition are carried out and it is understood that acetal can be removed by condition of 1N hydrochloric acid/methanol, and the total synthesis of CTX1B can be carried out for the first time. Further, at above mentioned development, the inventors considered to utilize HIJKLM ring segments compound A, which was already reported in a paper (non-patent document 3, J. Org. Chem. 69, 2797-2804 (2004)), and compound C (non-patent document 4, J. Org. Lett., 6, 751-754 (2004)) as one of intermediates, according to the thinking that O,S-acetal compound 3, which is the most important intermediate, can be synthesized by coupling reaction developed by the inventors that permits neutral condition.
SUBJECT OF THE INVENTION
The subject of the present invention is to provide an effective method for total synthesis of CTX1B by high yield. Aiming to accomplish said subject, the inventors of the present invention considered that the designing of an intermediate that can apply an established reaction to be considered rational in synthesis of ciguatoxin analogous compound is important. That is, the subject of this invention is to provide an useful compound that can be used for an effective method for total synthesis of CTX1B, further to link to an improvement of synthesis of ciguatoxin analogous compound.
From said points of view, the inventors of the present invention continued investigation and adopted O,S-acetal forming reaction that synthesizes compound 3, and 9-rings forming reaction from compound 6-8, further, developed a radical ring-forming reaction to obtain aforementioned compound D and a deprotection reaction to obtain CTX1B newly, and by synthesizing all new compounds to link the intermediate to aimed compound, and can accomplish the aforementioned subject.
DISCLOSURE OF THE INVENTION
The first one of the present invention is a method for synthesizing the aimed compound of CTX1B including following 10 processes. First process is comprised of oxidizing double bond in compound A by using osmium tetra oxide to change to a diol derivative of compound A, and after transforming the diol to an aldehyde by oxidation cleavage by using sodium periodate, reducing the aldehyde to alcohol using sodium borohydride to obtain compound 1 (process 1).




Second process is transforming the alcohol of compound 1 to compound 2 using diphenyldisulfide•tributylphosphine (process 2).





Third process comprises of transforming the compound 2 toα-chrolosulphide to synthesize the compound B, and synthesizing compound 3 by joining the ABCDE ring segments compound C (Refer to the non-patent document 4, J. Org. Lett., 6, 751-754 (2004)) and the compound B as O,S-acetal using silver triflate (AgOTf) (process 3), under the presence of DTBMP (2,6-di-t-butyl-4-methylpyridine).




(process 3).





Forth process is forming the compound 4 by removing TIPS (triisopropylsilyl) group from the compound 3 using TBAF (tetrabutylammonium fluoride) (process 4).





Fifth process is forming the compound 5 by joining pentafluorophenylpropiolate to alcohol of above mentioned compound 4 (process 5).





Sixth process comprises of transforming the compound 5 to carboxylic acid compound D by forming G ring part by carrying out radical cyclizing reaction on said compound 5 treating by AIBN (α,α′-azobis(isobutyronitrile)) and tributyltin hydride, and





transforming to methyl ester by acting trimethylsilyldiazomethane and to form compound 6 (process 6).





Seventh process is forming compound 7 by reducing methyl ester of above mentioned compound 6 by using diisobutylaluminum hydrate under lower temperature condition, then transforms to olefin by Wittig reaction (process 7).





Eighth process is forming compound 8 by forming F ring part by carrying out ring closure methathesis reaction acting Grubbs catalyst to above mentioned compound 7 (process 8).





Ninth process is synthesizing compound E, 1,2-diol of A ring side chain of which is protected by naphthylacetal, by oxidizing 6 NAP (2-naphthylmethyl) groups using DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone) and removing 5 NAP groups (process 9).





Tenth process is obtaining aimed compound CTX1B by acid treatment of above mentioned compound E (process 10).





The second one of the present invention is a novel compound represented by compound 1, which is useful for the method to prepare CTX1B. The third one of the present invention is a novel compound represented by compound 2, which is useful for the method to prepare CTX1B. The fourth one of the present invention is a novel compound represented by compound 3, which is useful for the method to prepare CTX1B. The fifth one of the present invention is a novel compound represented by compound 4, which is useful for the method to prepare CTX1B. The sixth one of the present invention is a novel compound represented by compound 5, which is useful for the method to prepare CTX1B. The seventh one of the present invention is a novel compound represented by compound 6, which is useful for the method to prepare CTX1B. The eighth one of the present invention is a novel compound represented by compound 7, which is useful for the method to prepare CTX1B. And the ninth one of the present invention is a novel compound represented by compound 8, which is useful for the method to prepare CTX1B.
EFFECT OF THE INVENTION
The offering of an effective total synthesis of CTX1B of the present invention is important from the view point that practical amount of said compound to ensure a progress in the research of biological science or a development for detection of Ciguatera poisoned fish can be supplied, and has an effect that can be practically used as a standard specimen of Ciguatera food-poisoning happened in all over the world.


PREFERRED EMBODIMENT OF THE INVENTION
The present invention will be illustrated more in detail. A. Since HIJKLM ring segments compound A (J. Org. Chem. 69, 2797-2804 (2004)), which was reported in afore mentioned non-patent document 3, has a structure corresponding to half of CTX1B, said compound A is used as an intermediate for synthesis of CTX1B. By reaction condition mentioned in following reaction formula, double bond of compound A is oxidized by osmium tetra oxide and transformed to diol, then transformed to aldehyde by oxidation cleavage by sodium periodate (at room temperature), after that, reduced to alcohol using sodium borohydride and obtain compound 1 (yield of these two processes is 91%).
Alcohol of compound 1 is transformed to compound 2 using diphenyldisulfide•tributylphosphine (at room temperature, yield is 96%).




Compound 2 is transformed to a α-chrolosulphide in 6:1 mixed solvent of carbon tetrachloride and dichloromethane using NSC and compound B is synthesized.
Then, ABCDE ring segments compound C, which is already reported in paper aforementioned non-patent document 4, J. Org. Lett., 6, 751-754 (2004)), and compound B are joined as O,S-acetal using silver triflate (AgOTf) in 1:5 mixed solvent of carbon tetrachloride and dichloromethane under the presence of DTBMP and compound 3 is obtained (yield to compound C is 63%).




TIPS group of compound 3 is removed by TBAF and compound 4 is formed (yield is 92%). Pentafluorophenylpropiolate acrylate is introduced into alcohol of compound 4 using pentafluorophenylpropiolate and trimethylphosphine and compound 5 is formed (yield is 94%).




Radical cyclizing reaction is carried out on compound 5 by treating with AIBN and tributyltin hydride in toluene at 85° C. and G ring part is formed, thus carboxylic acid compound D is obtained. In mixed solvent of benzene and methanol, trimethylsilyldiazomethane is acted to compound D so as to transform to methyl ester, and compound 6 is formed.




Methyl ester of compound 6 is reduced to aldehyde by diisobutylaluminum hydride under low temperature condition, then transformed to olefin by Wittig reaction and compound 7 is formed. Grubbs catalyst is acted to compound 7 and F ring part is formed by carrying out ring closure methathesis reaction, and compound 8 is obtained.




Six NAP groups of compound 8 are oxidized using DDQ and 5 NAP groups is removed, thus compound E characterized that 1,2-diol of A ring side chain is protected by naphthylacetal is formed. Finally, compound E is treated by 1N hydrochloric acid in methanol solvent and total synthesis of CTX1B, which is aimed compound, is accomplished.




EXAMPLES
More concrete synthesis will be shown as Examples, however, these Examples are shown to understand the present invention more easily and not intending the scope of the present invention.
Example 1
Synthesis of Compound 1




HIJKLM ring segments compound A (151 mg, 129 μmol) is dissolved in mixed solvent (0.1M) of THF (0.86 mL)-water (0.43 mL), then osmium tetra oxide (19 mM, t-BuOH solution, 710 μL, 13.4 μmol) and NMO (50% aqueous solution, 94 μL, 402 μmol) are added and stirred vigorously for 2 hours. To this solution, phosphoric acid buffer solution (pH=7.0, 3.0 mL, 0.04M) and sodium periodate (120 mg, 536 μmol) are added gradually and stirred at room temperature for 3 hours. Reaction is stopped by adding saturated Na2S2O3 aqueous solution to this solution and diluted by ethyl acetate and saturated NaHCO3 aqueous solution. Water phase is extracted by ethyl acetate for 3 times, and combined organic layer is washed by saturated brine, then is dried by Na2SO4. Solvent is concentrated and crude aldehyde is used to the next reaction without refining.
CH2Cl2 (5.0 mL, 0.25M) solution of aldehyde is cooled to 0° C., and sodium borohydride (25 mg, 670 μmol) is added and stirred for 30 minutes. Reaction is stopped by adding saturated NH4Cl aqueous solution into this solution and diluted by ethyl acetate. Water phase is extracted by ethyl acetate for 3 times, and combined organic layer is washed by saturated brine, then is dried by Na2SO4. Solvent is concentrated and refined by a flash column, then alcohol of compound 1 (138 mg, 1.17 μmol) is obtained. Total yield of this 2 processes is 91%. Features of compound 1 are shown in Table 1.







TABLE 1







[α]D23 −10.3 (c 0.41, CHCl3); IR (film) ν 2926, 2865, 1723, 1463, 1090 cm−1


1H NMR (500 MHz, CDCl3) δ 7.83-7.41 (21H, m, NAP × 3), 4.81 (1H, d, J = 12.0 Hz,


NAP), 4.79 (1H, d, J = 12.0 Hz, NAP), 4.73 (1H, d, J = 12.0 Hz,


NAP), 4.66 (1H, d, J = 12.0 Hz, NAP), 4.61 (1H, d, J = 12.0 Hz, NAP),


4.58 (1H, d, J = 12.0 Hz, NAP), 4.31 (1H, dd, J = 11.5, 5.0 Hz, H34), 4.26 (1H, m,


H54), 3.97 (1H, dd, J = 9.5, 1.5 Hz, H55), 3.88-3.80 (4H, m, H30, H32, H44,


H55), 3.64 (1H, m, H30), 3.61 (1H, d, J = 9.5 Hz, H48), 3.43-3.41 (2H, m,


H47, H49), 3.39 (1H, ddd, J = 9.5, 3.5, 3.5 Hz, H37), 3.15 (1H, ddd, J = 11.5,


9.5, 5.0 Hz, H36), 3.10 (1H, ddd, J = 11.5, 9.5, 5.0 Hz, H42), 2.98 (1H, ddd, J = 9.5,


2.5, 2.5 Hz, H41), 2.84 (1H, dd, J = 9.0, 4.0 Hz, H45), 2.25-2.14 (6H,


m, H31, H35, H43, H46, H53, H53), 1.95 (1H, m, H31), 1.89-1.77 (3H, m,


H38, H39, H40), 1.73 (1H, ddd, J = 11.5, 11.5, 11.5 Hz, H35), 1.67-1.53 (4H,


m, H38, H40, H50, H51), 1.39 (1H, ddd, J = 11.5, 11.5, 11.5 Hz, H43),


1.18 (3H, S, Me56), 1.09 (3H, d, J = 7.5 Hz, Me58), 1.07-1.02 (30H, m, TIPS,


Me57, Me59, Me60)


13C NMR (125 MHz, CDCl3) δ136.7, 136.3, 135.6, 133.26, 133.24, 133.1,


132.9, 132.8, 128.1, 127.9, 127.86, 127.83, 127.74, 127.72, 127.69, 127.65,


126.2, 126.14, 126.12, 126.0, 125.9, 125.8, 125.68, 125.65, 108.9, 86.7, 84.6,


82.9, 80.8, 80.0, 79.6, 78.5, 77.8, 74.1, 73.7, 72.1, 71.9, 71.8, 71.4, 71.1, 68.0,


58.7, 42.5, 41.6, 40.4, 40.0, 38.4, 38.2, 31.5, 29.9, 27.5, 22.6, 19.9, 18.4, 18.3,


18.19, 18.14, 15.9, 14.1, 14.0, 13.5, 13.4, 13.0, 12.9


MALDI-TOF MS, calcd. for C74H96NaO10Si 1199.6620 (M + Na+), found for


1199.6620









Synthesis of Compound 2





Into pyridine (1.2 mL, 0.1M) solution of compound 1 (138 mg, 117 μmol), PhSSP (153 mg, 702 μmol) and n-PBu3 (175 μL, 702 μmol) are added and stirred at room temperature for 6 hours. Reaction is stopped by adding saturated NH4Cl aqueous solution into this solution and diluted by ethyl acetate. Water phase is extracted by ethyl acetate for 3 times, and combined organic layer is washed by saturated brine, then is dried by Na2SO4. Solvent is concentrated and refined by a flash column, then thiophenylether of compound 2 (143 mg, 113 μmol, 96%) is obtained. Features of compound 2 are shown in Table 2.








TABLE 2







[α]D25 −3.3 (c 0.47, CHCl3); IR (film) ν 2927, 2858, 1708, 1464, 1093,


1030 cm−1


1H NMR (500 MHz, CDCl3) δ 7.83-7.11 (26H, m, NAP × 3, PhS), 4.81 (1H, d,


J = 12.0 Hz, NAP), 4.81 (1H, d, J = 12.5 Hz, NAP), 4.76 (1H, d, J = 12.5 Hz,


NAP), 4.75 (1H, d, J = 12.0 Hz, NAP), 4.62 (1H, d, J = 12.0 Hz, NAP),


4.59 (1H, d, J = 12.0 Hz, NAP), 4.27 (1H, m, H54), 4.21 (1H, dd, J = 12.0, 5.0 Hz,


H34), 3.98 (1H, d, J = 9.5 Hz, H55), 3.86 (1H, ddd, J = 12.0, 9.0, 5.0 Hz,


H44), 3.83 (1H, dd, J = 9.5, 5.5 Hz, H55), 3.77 (1H, dd, J = 7.5, 3.5 Hz, H32),


3.62 (1H, d, J = 9.5 Hz, H48), 3.64 (1H, m, H30), 3.44 (1H, d, J = 3.5 Hz,


H47), 3.43 (1H, dd, J = 9.5, 9.5 Hz, H49), 3.30 (1H, ddd, J = 10.0, 10.0, 3.0 Hz,


H37), 3.17 (1H, ddd, J = 13.5, 9.0, 4.5 Hz, H30), 3.11 (1H, ddd, J = 12.0,


10.0, 5.0 Hz, H42), 3.09 (1H, ddd, J = 12.0, 10.0, 5.0 Hz, H36), 3.00 (1H, ddd,


J = 10.0, 10.0, 2.5 Hz, H41), 2.93 (1H, ddd, J = 13.5, 8.5, 7.5 Hz, H30),


2.86 (1H, dd, J = 9.0, 4.5 Hz, H45), 2.20 (1H, ddd, J = 12.0, 5.0, 5.0 Hz, H43),


2.18 (1H, m, H46), 2.16 (1H, m, H53), 2.15 (1H, m, H53), 2.13 (1H, ddd, J = 12.0,


5.0, 5.0 Hz, H35), 2.10 (1H, m, H31), 2.00 (1H, m, H31), 1.86 (1H, m,


H40), 1.82 (1H, m, H39), 1.79 (1H, m, H36), 1.72 (1H, ddd, J = 12.0, 12.0,


12.0 Hz, H35), 1.61 (1H, m, H50), 1.59 (1H, m, H51), 1.56 (1H, m, H36),


1.54 (1H, m, H40), 1.39 (1H, ddd, J = 12.0, 12.0, 12.0 Hz, H43), 1.12 (3H, S,


Me56), 1.09 (3H, d, J = 7.5 Hz, Me58), 1.07 (3H, d, J = 7.0 Hz, Me57),


1.06 (3H, d, J = 7.0 Hz, Me59), 1.04 (21H, m, TIPS), 1.02 (3H, m, Me60)


13C NMR (125 MHz, CDCl3) δ 136.8, 136.74, 136.17, 135.6, 133.25, 133.23,


133.1, 132.9, 132.8, 132.7, 128.7, 128.6, 128.1, 127.85, 127.83, 127.73,


127.71, 127.68, 127.63, 126.2, 126.1, 126.0, 125.98, 125.92, 125.8, 125.7,


125.68, 125.64, 125.61, 125.5, 108.9, 86.6, 84.5, 82.9, 80.9, 80.8, 80.1, 78.5,


77.8, 74.2, 73.4, 72.1, 71.8, 71.4, 71.1, 68.5, 60.4, 42.4, 41.5, 40.5, 40.0, 38.4,


38.3, 30.3, 29.6, 28.1, 27.5, 21.0, 19.9, 18.46, 18.43, 18.38, 18.34, 18.2, 18.1,


15.9, 14.17, 14.11, 13.8, 13.5, 13.4, 13.0


MALDI-TOF MS, calcd. for C76H102NaO10SSi 1291.6704 (M + Na+), found for


1291.6624









Synthesis of Compound 3





N-chlorosuccinimide (2.67 mg, 20 μmol) is dissolved in CH2Cl2 (50 μL) and added into CCl4 (280 μL, 0.07M) solution of compound 2 (24.6 mg, 19.4 μmol) solution, stirred at room temperature for 2 hours and compound B is formed. This solution is dropped slowly into −80° C. cooled CH2Cl2 solution of compound C (11.2 mg, 12.1 mol), silver triflate (7.5 mg, 32.3 μmol), DTBMP (13.3 mg, 64.5 μmol) and activated MS4A (40 mg), stirred for 2 hours and elevated the temperature to −10° C. This reacted solution is filtrated by 0° C. cooled open column and concentrated. After that, refined by a flash column and compound 3, O,S-acetal (16.6 mg, 7.57 μmol, 63%) is obtained. Features of compound 3 are shown in Table 3.







TABLE 3







[α]D23 4.5 (c 1.00, CH2Cl2); IR (film) ν 2927, 2865, 1775, 1716, 1459, 1344,


1291, 1090, 816 cm−1;


1H NMR (500 MHz, C6D6) δ 8.02-6.92 (47H, m, NAP × 6, PhS), 6.11 (1H, ddd,


J = 13.0, 2.5, 2.5 Hz, H22), 5.98 (1H, dd, J = 15.0, 2.5 Hz, H4), 5.93 (1H, dd,


J = 15.0, 2.5 Hz, H3), 5.84 (1H, dddd, J = 17.0, 10.0, 5.5, 5.5 Hz, H26),


5.79 (1H, d, J = 11.5 Hz, H17), 5.78 (1H, d, J = 11.5 Hz, H18), 5.70 (1H, ddd, J = 11.5,


3.0, 3.0 Hz, H6), 5.61 (1H, ddd, J = 13.0, 2.5, 2.5 Hz, H21), 5.53 (1H, m,


H7), 5.33 (1H, dd, J = 10.0, 3.0, 3.0 Hz, H30), 5.24 (2H, s, NAP), 5.21 (1H, d,


J = 12.5 Hz, NAP), 5.14 (1H, d, J = 12.5 Hz, NAP), 5.06 (1H, dd, J = 17.0,


2.0 Hz, H26′), 4.98 (1H, dd, J = 10.0, 2.0 Hz, H26′), 4.86 (1H, d, J = 12.5 Hz,


NAP), 4.82 (1H, d, J = 12.5 Hz, NAP), 4.81 (1H, d, J = 12.0 Hz, NAP),


4.62 (1H, d, J = 12.0 Hz, NAP), 4.54 (1H, m, H5), 4.51 (2H, s, NAP), 4.47 (1H, dd,


J = 12.0, 5.0 Hz, H34), 4.38 (1H, dd, J = 10.0, 3.0 Hz, H32), 4.32 (2H, s,


NAP), 4.23 (1H, m, H23), 4.20 (1H, m, H2), 4.18 (1H, m, H19), 4.15 (1H, m,


H44), 4.08 (1H, m, H54), 4.04 (1H, d, J = 10.0 Hz, H55), 3.96 (1H, d, J = 9.5 Hz,


H48), 3.91 (1H, m, H20), 3.78 (1H, dd, J = 10.0, 5.0 Hz, H55), 3.75 (1H,


dd, J = 10.0, 2.0 Hz, H1), 3.73 (1H, dd, J = 9.5, 9.5 Hz, H49), 3.71 (1H, d, J = 8.0 Hz,


H16), 3.67 (1H, dd, J = 9.0, 9.0 Hz, H11), 3.65 (1H, m, H24),


3.62 (1H, d, J = 3.0 Hz, H47), 3.56 (1H, dd, J = 9.0, 9.0 Hz, H10), 3.52 (1H, dd, J = 10.0,


4.5 Hz, H1), 3.32 (1H, m, H37), 3.30 (1H, ddd, J = 9.0, 9.0, 5.5 Hz,


H9), 3.19 (1H, dd, J = 9.0, 9.0 Hz, H12), 3.11 (1H, m, H15), 3.10 (1H, m,


H41), 3.03 (1H, dd, J = 9.5, 5.0 Hz, H45), 3.02 (1H, m, H36), 2.99 (1H, m,


H42), 2.93 (1H, ddd, J = 11.5, 9.0, 4.5 Hz, H13), 2.85 (1H, m, H31), 2.59 (1H,


ddd, J = 16.0, 9.0, 4.5 Hz, H8), 2.53 (1H, m, H25), 2.51 (1H, m, H31),


2.49 (1H, m, H46), 2.47 (1H, m, H43), 2.33 (1H, m, H8), 2.31 (1H, m, H35),


2.29 (1H, m, H14), 2.23 (1H, m, H53), 2.21 (1H, m, H53), 2.20 (1H, m, H25),


2.03 (1H, m, H40), 1.97 (1H, m, H50), 1.95 (1H, m, H35), 1.92 (1H, m, H38),


1.83 (1H, m, H39), 1.77 (1H, ddd, J = 12.0, 12.0, 12.0 Hz, H43), 1.67 (1H, ddd, J = 1.5,


11.5, 11.5 Hz, H14), 1.63 (1H, m, H40), 1.59 (1H, m, H38), 1.54 (1H,


m, H51), 1.13 (3H, m, Me58), 1.13 (21H, m, TIPS), 1.12 (3H, m, Me56),


1.11 (3H, d, J = 6.5 Hz, Me59), 1.08 (3H, d, J = 7.0 Hz, Me60), 0.98 (3H, d, J = 7.0 Hz,


Me57);


13C NMR (125 MHz, C6D6) δ 176.5, 137.6, 137.5, 137.3, 136.9, 136.7, 136.43,


136.41, 135.1, 134.4, 134.2, 134.05, 133.99, 133.97, 133.95, 133.92, 133.57,


133.54, 133.52, 133.4, 133.3, 131.4, 131.1, 129.2, 129.1, 128.48, 128.45,


128.41, 128.35, 128.19, 128.16, 128.13, 128.12, 128.0, 127.7, 126.9, 126.67,


126.65, 126.57, 126.55, 126.46, 126.44, 126.34, 126.29, 126.23, 126.20,


126.15, 126.12, 126.05, 126.02, 126.00, 125.98, 125.92, 125.86, 125.79, 117.4,


109.5, 89.9, 87.3, 85.6, 84.6, 83.5, 83.1, 82.2, 81.8, 81.5, 80.8, 80.5, 79.9,


79.3, 79.2, 79.1, 78.6, 78.2, 76.8, 75.3, 74.7, 74.3, 73.9, 73.5, 73.1, 72.9, 72.8,


71.7, 71.3, 71.1, 68.9, 68.1, 60.1, 43.2, 42.2, 41.5, 40.9, 39.2, 39.1, 38.2, 37.6,


34.9, 34.7, 31.7, 30.2, 29.2, 28.1, 20.2, 18.73, 18.69, 16.3, 14.4, 13.9, 13.6,


11.2


MALDI-TOF MS, calcd. for C139H158NaO19SSi 2214.0780 (M + Na+), found


for 2213.9349









Synthesis of Compound 4





TBAF (1.0M THF solution, 23 μL, 23 μmol) is added to THF (300 μL, 0.02M) solution of compound 3 (12.6 mg, 5.74 μmol) and stirred at 35° C. for 4 hours. After this solution is concentrated, refined using a flush column and alcohol of compound 4 (10.78 mg, 5.30 μmol, 92%) is obtained. Features of compound 4 are shown in Table 4.








TABLE 4







[α]D23 10.2 (c 1.00, CH2Cl2); IR (film) ν 3221, 2926, 1775, 1715, 1456, 1347,


1177, 1088, 817 cm−1;


1H NMR (500 MHz, C6D6) δ 7.99-6.98 (47H, m, NAP × 6, PhS), 6.14 (1H, ddd,


J = 13.0, 3.0, 3.0 Hz, H22), 5.99 (1H, dd, J = 16.0, 1.5 Hz, H4), 5.96 (1H, dd,


J = 16.0, 1.5 Hz, H3), 5.86 (1H, d, J = 12.5 Hz, H17), 5.84 (1H, d, J = 12.5 Hz,


H18), 5.78 (1H, dddd, J = 17.0, 10.5, 6.5, 6.5 Hz, H26), 5.71 (1H, ddd, J = 13.0,


3.0, 3.0 Hz, H21), 5.69 (1H, ddd, J = 11.5, 3.0, 3.0 Hz, H6), 5.52 (1H,


dddd, J = 11.5, 7.0, 4.0, 3.5 Hz, H7), 5.23 (2H, s, NAP), 5.20 (1H, dd, J = 7.0,


6.5 Hz, H30), 5.01 (1H, dd, J = 17.0, 2.5 Hz, H26′), 4.98 (1H, dd, J = 10.0,


2.5 Hz, H26′), 4.88 (1H, d, J = 12.5 Hz, NAP), 4.85 (1H, d, J = 12.5 Hz,


NAP), 4.82 (1H, d, J = 12.0 Hz, NAP), 4.70 (1H, d, J = 12.0 Hz, NAP),


4.65 (1H, d, J = 12.0 Hz, NAP), 4.62 (1H, d, J = 12.0 Hz, NAP), 4.53 (1H, m, H5),


4.52 (1H, d, J = 12.0 Hz, NAP), 4.49 (1H, d, J = 12.0 Hz, NAP), 4.40 (1H,


ddd, J = 8.0, 3.0, 3.0 Hz, H23), 4.34 (2H, s, NAP), 4.28 (1H, dd, J = 9.0, 3.0 Hz,


H19), 4.21 (1H, m, H44), 4.19 (1H, m, H2), 4.09 (1H, m, H54),


4.07 (1H, d, J = 9.5 Hz, H55), 4.01 (1H, m, H20), 3.96 (1H, d, J = 8.5 Hz, H48),


3.96 (1H, m, H32), 3.95 (1H, m, H34), 3.83 (1H, d, J = 8.0 Hz, H16),


3.82 (1H, dd, J = 8.5, 8.5 Hz, H49), 3.81 (1H, dd, J = 9.5, 4.5 Hz, H55), 3.70 (1H,


dd, J = 9.0, 9.0 Hz, H11), 3.69 (1H, dd, J = 10.5, 3.0 Hz, H1), 3.66 (1H, d, J = 3.0 Hz,


H47), 3.61 (1H, ddd, J = 8.0, 4.0 Hz, H24), 3.53 (1H, dd, J = 10.5,


4.5 Hz, H1), 3.51 (1H, dd, J = 9.0, 9.0 Hz, H10), 3.30 (1H, m, H9), 3.28 (1H,


m, H37), 3.16 (1H, dd, J = 9.0, 9.0 Hz, H12), 3.13 (1H, m, H15), 3.07 (1H, dd,


J = 9.5, 4.5 Hz, H45), 3.05 (1H, m, H41), 2.92 (1H, ddd, J = 11.5, 9.0, 4.0 Hz,


H13), 2.88 (1H, m, H42), 2.71 (1H, m, H31), 2.70 (1H, m, H36), 2.59 (1H,


ddd, J = 15.5, 8.0, 4.0 Hz, H8), 2.56 (1H, m, H46), 2.49 (1H, m, H25),


2.46 (1H, m, H31), 2.41 (1H, ddd, J = 13.0, 5.0, 5.0 Hz, H43), 2.32 (1H, ddd, J = 11.5,


4.0, 4.0 Hz, H14), 2.29 (1H, m, H8), 2.24 (1H, m, H53), 2.23 (1H, m,


H53), 2.20 (1H, m, H25), 2.16 (1H, m, H35), 2.05 (1H, m, H50), 2.02 (1H, m,


H40), 1.78 (1H, m, H39), 1.76 (1H, m, H35), 1.72 (1H, ddd, J = 12.5, 12.5,


12.5 Hz, H43), 1.70 (1H, ddd, J = 1.5, 11.5, 11.5 Hz, H14), 1.60 (1H, m, H38),


1.56 (1H, m, H51), 1.52 (1H, m, H40), 1.32 (3H, s, Me56), 1.27 (3H, d, J = 6.5 Hz,


Me59), 1.18 (1H, m, H38), 1.17 (3H, d, J = 7.5 Hz, Me60), 1.16 (3H,


d, J = 6.5 Hz, Me58), 0.93 (3H, d, J = 7.5 Hz, Me57)


13C NMR (125 MHz, C6D6) δ 176.4, 137.6, 137.3, 136.9, 136.7, 136.4, 135.4,


135.0, 134.4, 134.00, 133.99, 133.97, 133.95, 133.94, 133.8, 133.7, 133.58,


133.55, 133.52, 132.8, 132.6, 131.0, 129.3, 129.1, 128.8, 128.47, 128.42,


128.35, 128.2, 128.0, 127.7, 127.5, 126.88, 126.85, 126.67, 126.65, 126.59,


126.56, 126.52, 126.49, 126.47, 126.45, 126.38, 126.33, 126.29, 126.23,


126.14, 126.08, 126.00, 125.93, 125.89, 117.4, 109.6, 89.8 87.34, 87.27, 85.57,


85.52, 84.4, 83.8, 83.59, 83.54, 83.49, 83.1, 82.2, 81.8, 81.5, 80.9, 80.04,


79.99, 79.2, 78.6, 77.5, 76.8, 75.4, 74.9, 73.9, 73.6, 73.5, 72.9, 71.7, 71.3,


71.1, 67.5, 46.7, 46.2, 43.3, 42.3, 41.3, 40.8, 39.2, 38.5, 37.8, 37.6, 37.3, 34.9,


32.0, 30.2, 28.6, 27.9, 23.0, 20.2, 16.3, 14.4;


MALDI-TOF MS, calcd. for C130H138NaO19S 2057.9451 (M + Na+), found for


2057.5975









Synthesis of Compound 5





Into CH2Cl2 (300 μL, 0.02M) solution of compound 4 (6.7 mg, 3.29 μmol) and pentaphenylpropiorate (3.1 mg, 13.2 μmol), PMe3 (1.0M THF solution, 6.6 μL, 6.6 μmol) is added and stirred at room temperature for 30 minutes. Further, same process to add same equivalent of pentaphenylpropiorate and PMe3 and to stir at room temperature for 30 minutes is repeated for 4 times. After this solution is concentrated, refined using a flush column and acrylate of compound 5 (7.0 mg, 3.08 μmol, 94%) is obtained. Features of compound 5 are shown in Table 5.







TABLE 5







[α]D24−6.7 (c 1.00, CH2Cl2); IR (film) ν 3055, 2925, 1750, 1637, 1520, 1457,


1088, 817 cm−1;


1H NMR (500 MHz, C6D6) δ 7.99-7.00 (47H, m, NAP × 6, PhS), 7.69 (1H, d, J = 12.0 Hz,


H29), 6.14 (1H, ddd, J = 12.5, 2.5, 2.5 Hz, H22), 5.99 (1H, dd, J = 16.0,


2.5 Hz, H4), 5.96 (1H, dd, J = 16.0, 2.5 Hz, H3), 5.88 (1H, dddd, J = 17.0,


10.5, 7.0, 7.0 Hz, H26), 5.84 (1H, d, J = 13.0 Hz, H17), 5.82 (1H, d, J = 13.0 Hz,


H18), 5.69 (1H, ddd, J = 12.5, 2.5, 2.5 Hz, H21), 5.67 (1H, ddd, J = 13.0,


2.0, 2.0 Hz, H6), 5.58 (1H, d, J = 12.0 Hz, H28), 5.53 (1H, m, H7),


5.26 (1H, dd, J = 10.0, 4.5 Hz, H30), 5.24 (2H, s, NAP), 5.10 (1H, dd, J = 17.0, 2.0 Hz,


H26′), 4.98 (1H, dd, J = 10.5, 2.0 Hz, H26′), 5.00 (1H, d, J = 11.5 Hz,


NAP), 4.92 (1H, d, J = 11.5 Hz, NAP), 4.85 (2H, s, NAP), 4.81 (1H, d, J = 12.0 Hz,


NAP), 4.62 (1H, d, J = 12.0 Hz, NAP), 4.53 (1H, m, H5), 4.51 (2H, s,


NAP), 4.33 (2H, s, NAP), 4.30 (1H, m, H23), 4.23 (1H, m, H44), 4.21 (1H, m,


H2), 4.18 (1H, m, H19), 4.09 (1H, m, H54), 4.06 (1H, m, H34), 3.99 (1H, d, J = 9.0 Hz,


H48), 3.98 (1H, m, H20), 3.97 (1H, m, H32), 3.96 (1H, m, H55),


3.81 (1H, dd, J = 9.0, 9.0 Hz, H49), 3.80 (1H, dd, J = 9.5, 4.5 Hz, H55),


3.77 (1H, d, J = 10.0 Hz, H16), 3.71 (1H, dd, J = 9.0, 9.0 Hz, H11), 3.68 (1H, dd, J = 10.0,


7.0 Hz, H1), 3.66 (1H, d, J = 3.5 Hz, H47), 3.61 (1H, m, H24),


3.56 (1H, dd, J = 9.0, 9.0 Hz, H10), 3.52 (1H, dd, J = 10.0, 4.0 Hz, H1), 3.31 (1H,


ddd, J = 9.0, 9.0, 4.5 Hz, H9), 3.21 (1H, m, H37), 3.20 (1H, dd, J = 9.0, 9.0 Hz,


H12), 3.12 (1H, ddd, J = 11.5, 10.0, 5.0 Hz, H15), 3.06 (1H, dd, J = 9.5,


5.0 Hz, H45), 3.03 (1H, m, H41), 2.92 (1H, ddd, J = 11.5, 9.0, 5.0 Hz, H13),


2.89 (1H, m, H42), 2.73 (1H, m, H36), 2.62 (1H, m, H8), 2.60 (1H, m, H31),


2.57 (1H, m, H46), 2.54 (1H, m, H25), 2.40 (1H, m, H31), 2.35 (1H, m, H8),


2.32 (1H, m, H43), 2.29 (1H, m, H14), 2.27 (1H, m, H25), 2.23 (1H, m, H53),


2.22 (1H, m, H53), 2.03 (1H, m, H50), 2.00 (1H, m, H40), 1.86 (1H, m, H35),


1.76 (1H, m, H38), 1.72 (1H, m, H39), 1.68 (1H, ddd, J = 11.5, 11.5, 11.5 Hz,


H43), 1.68 (1H, ddd, J = 1.5, 11.5, 11.5 Hz, H14), 1.59 (1H, m, H35),


1.56 (1H, m, H40), 1.54 (1H, m, H51), 1.36 (1H, m, H38), 1.25 (3H, d, J = 6.0 Hz,


Me59), 1.16 (3H, d, J = 7.5 Hz, Me58), 1.14 (3H, d, J = 7.0 Hz, Me60),


1.02 (3H, s, Me56), 0.91 (3H, d, J = 7.5 Hz, Me57);


13C NMR (125 MHz, C6D6) δ 165.21, 163.52, 142.9, 142.8, 141.6, 140.9,


140.4, 139.2, 139.1, 137.9, 137.6, 137.1, 136.9, 136.7, 136.5, 136.4, 135.4,


135.0, 134.4, 134.00, 133.99, 133.97, 133.95, 133.93, 133.91, 133.58, 133.56,


133.52, 133.47, 133.37, 131.6, 130.9, 129.4, 129.3, 129.1, 128.7, 128.6, 128.5,


128.42, 128.38, 128.37, 128.35, 128.14, 128.12, 128.0, 126.9, 126.8, 126.65,


126.64, 126.60, 126.58, 126.55, 126.52, 126.48, 126.46, 126.39, 126.37,


126.29, 126.27, 126.23, 126.22, 126.15, 126.10, 125.99, 125.92, 125.88,


125.75, 125.70, 117.6, 109.5, 95.7, 89.0 87.4, 87.3, 85.5, 84.6, 83.7, 83.5, 83.4,


82.4, 82.3, 81.8, 81.7, 81.5, 80.8, 79.34, 79.30, 79.2, 79.1, 78.6, 78.0, 76.8,


75.4, 74.8, 74.4, 73.9, 73.8, 73.6, 73.5, 72.9, 72.8, 71.8, 71.3, 71.1, 46.57,


46.0, 43.3, 42.2, 41.2, 40.9, 39.2, 38.2, 37.6, 36.5, 34.9, 34.7, 30.5, 30.2, 28.4,


27.9, 20.2, 16.3, 14.0, 13.7;


MALDI-TOF MS, calcd. for C139H139F5NaO21S 2293.9347 (M + Na+), found


for 2293.9377









Synthesis of Compound 6





Degassed toluene (4.3 mL, 0.001M) solution of compound 5 (6.7 mg, 3.29 μmol), AIBN (7.1 mg, 43 μmol) and n-Bu3SnH (58 μL, 215 μmol) is heated to 85° C. and stirred for 3 hours. After this solution is cooled down, refined directly using a flush column and carboxylic acid of compound D (5.0 mg, 2.50 μmol, 59%) is obtained. Compound D is not refined more and used to the next reaction.
TMSCHN2 (2.0M hexane solution, 13 μL, 25 μmol) is added into mixed solution (0.01M) of benzene (0.86 mL) methanol (0.43 mL) of carboxylic acid (5.0 mg, 2.50 μmol) of compound D and stirred for 30 minutes, This solution is diluted by benzene and water, and reaction is stopped by dropping acetic acid. Ethyl acetate and saturated NaHCO3 aqueous solution, and water phase is extracted by ethyl acetate for 3 times. Organic layer is washed by saturated brine and dried by Na2SO4. Solvent is concentrated, refined by a flush column and methyl ester (4.2 mg, 2.09 μmol, 84%) of compound 6 is obtained. Features of compound 6 are shown in Table 6.







TABLE 6







[α]D25 10.6 (c 0.50, CH2Cl2); IR (film) ν 2924, 2854, 1738, 1456, 1334,


1270, 1089, 817 cm−1;


1H NMR (500 MHz, C6D6) δ 7.99-7.01 (42H, m, NAP × 6), 6.00 (1H, dd, J = 16.0,


2.0 Hz, H4), 5.96 (1H, dd, J = 16.0, 2.0 Hz, H3), 5.95 (1H, dddd, J = 17.0,


10.5, 7.0, 7.0 Hz, H26), 5.86 (1H, d, J = 13.0 Hz, H17), 5.84 (1H, d, J = 13.0 Hz,


H18), 5.69 (1H, ddd, J = 11.0, 3.0, 3.0 Hz, H6), 5.53 (1H, d, J = 11.0 Hz,


H21), 5.52 (1H, m, H7), 5.51 (1H, d, J = 11.0 Hz, H22), 5.23 (2H, s,


NAP), 5.23 (1H, d, J = 12.5 Hz, NAP), 5.17 (1H, dd, J = 17.0, 3.0 Hz, H26′),


5.07 (1H, dd, J = 10.5, 3.0 Hz, H26′), 5.01 (1H, d, J = 12.5 Hz, NAP),


4.87 (1H, d, J = 12.5 Hz, NAP), 4.84 (1H, d, J = 12.5 Hz, NAP), 4.81 (1H, d, J = 12.0 Hz,


NAP), 4.62 (1H, d, J = 12.0 Hz, NAP), 4.54 (1H, m, H5), 4.51 (2H, s,


NAP), 5.42 (1H, dd, J = 7.0, 7.0 Hz, H29), 4.33 (2H, s, NAP), 4.27 (1H, d, J = 9.0 Hz,


H19), 4.19 (1H, m, H44), 4.17 (1H, m, H2), 4.09 (1H, m, H54),


4.06 (1H, d, J = 10.5 Hz, H30), 3.99 (1H, d, J = 9.5 Hz, H23), 3.98 (1H, m, H55),


3.96 (1H, d, J = 9.0 Hz, H20), 3.83 (1H, d, J = 10.0 Hz, H16), 3.81 (1H, m,


H55), 3.80 (1H, m, H32), 3.69 (1H, dd, J = 9.0, 3.5 Hz, H1), 3.68 (1H, dd, J = 9.0,


9.0 Hz, H11), 3.68 (1H, d, J = 9.0 Hz, H48), 3.65 (1H, d, J = 3.0 Hz,


H47), 3.63 (1H, m, H34), 3.60 (1H, m, H24), 3.53 (1H, dd, J = 9.0, 3.5 Hz,


H1), 3.52 (1H, dd, J = 9.0, 9.0 Hz, H49), 3.49 (1H, m, H37), 3.43 (1H, dd, J = 9.0,


9.0 Hz, H10), 3.31 (3H, s, MeO), 3.30 (1H, m, H9), 3.15 (1H, ddd, J = 11.5,


10.0, 4.5 Hz, H15), 3.10 (1H, m, H41), 3.09 (1H, dd, J = 9.0, 9.0 Hz,


H12), 3.06 (1H, dd, J = 9.5, 4.5 Hz, H45), 2.98 (1H, m, H36), 2.94 (1H, m,


H42), 2.92 (1H, m, H13), 2.58 (1H, m, H8), 2.57 (1H, m, H25), 2.55 (1H, m,


H46), 2.44 (1H, dd, J = 11.0, 7.0 Hz, H28), 2.40 (1H, m, H14), 2.38 (1H, m,


H25), 2.36 (1H, m, H43), 2.34 (1H, m, H8), 2.24 (1H, m, H53), 2.23 (1H, m,


H53), 2.14 (1H, dd, J = 11.0, 7.0 Hz, H28), 2.11 (1H, m, H35), 2.08 (1H, m,


H50), 2.07 (1H, m, H31), 2.03 (1H, m, H38), 2.01 (1H, m, H40), 1.89 (1H, m,


H31), 1.86 (1H, m, H35), 1.85 (1H, m, H39), 1.72 (1H, ddd, J = 11.5, 11.5,


11.5 Hz, H43), 1.70 (1H, ddd, J = 1.5, 11.5, 11.5 Hz, H14), 1.65 (1H, m, H40),


1.59 (1H, m, H38), 1.57 (1H, m, H51), 1.29 (3H, s, Me56), 1.26 (3H, d, J = 6.0 Hz,


Me59), 1.15 (3H, d, J = 6.5 Hz, Me58), 1.10 (3H, d, J = 8.0 Hz,


Me60), 0.96 (3H, d, J = 7.0 Hz, Me57);


13C NMR (125 MHz, C6D6) δ 170.80, 137.9, 137.7, 137.3, 136.9, 136.7,


136.5, 135.3, 135.2, 134.4, 134.3, 134.2, 134.04, 133.99, 133.96, 133.94,


133.61, 133.59, 133.55, 133.53, 131.4, 130.0, 129.3, 129.2, 128.6, 128.46,


128.42, 128.38, 128.35, 128.30, 128.16, 128.14, 128.0, 126.9, 126.8, 126.66,


126.63, 126.58, 126.55, 126.47, 126.44, 126.35, 126.29, 126.22, 126.13,


126.06, 125.99, 125.94, 125.88, 125.7, 117.4, 109.5, 87.4, 87.1, 85.6, 84.2,


83.8, 83.4, 82.4, 82.2, 81.74, 81.66, 81.2, 80.9, 80.26, 80.22, 80.1, 79.4, 79.22,


79.18, 78.6, 78.5, 76.8, 75.3, 74.9, 74.1, 73.9, 73.6, 73.5, 72.9, 72.8, 71.7,


71.3, 71.1, 47.2, 46.3, 43.3, 42.3, 41.4, 40.7, 39.9, 39.2, 38.5, 37.6, 36.1, 34.9,


32.6, 32.4, 32.0, 28.2, 27.1, 23.1, 20.2, 17.3, 16.4, 14.0, 13.8, 9.7;


MALDI-TOF MS, calcd. for C128H138NaO21 2033.9628 (M + Na+), found for


2033.9634









Synthesis of Compound 7





DIBAL solution (0.9M hexane solution, 17 μL, 15.1 μmol) is dropped slowly to compound 6 (3.2 mg, 1.51 μmol), which is cooled down to −100° C., stirred for 30 minutes and elevate the temperature to −90° C. Reaction is stopped by adding Ethyl acetate and saturated NH4Cl aqueous solution and diluted by ethyl acetate. Water layer is extracted by ethyl acetate for 3 times and combined organic layer is washed by saturated brine and dried by Na2SO4. Solvent is concentrated and crude aldehyde is obtained. This aldehyde is not refined and used in next reaction.
THF (1.0 mL, 0.001M) of triphenylphosphonium bromide (54 mg, 151 μmol) is treated with t-BuOK (8.4 mg, 75 μmol) at 0° C., and mixture is stirred at 0° C. for 20 minutes. THF solution (0.5 mL) of aldehyde is introduced and is stirred at 0° C. for 30 minutes. Reaction is stopped by adding saturated NH4Cl aqueous solution and water solution is extracted by ethyl acetate. Organic layer is washed with saturated brine, then dried by Na2SO4. Solvent is concentrated and refined by a flush column and hexaene (2.3 mg, 1.16 μmol, total of two process is 77%) of compound 7 is obtained. Features of compound 7 are shown in Table 7.







TABLE 7







[α]D27 2.2 (c 0.50, CH2Cl2); IR (film) ν 2924, 1727, 1514, 1438, 1262, 1175,


1089, 818 cm−1;


1H NMR (500 MHz, C6D6) δ 7.99-7.01 (42H, m, NAP × 6), 5.99 (1H, m, H4),


5.97 (1H, m, H3), 5.92 (1H, dddd, J = 17.0, 10.0, 7.0, 7.0 Hz, H26), 5.88 (1H,


dddd, J = 17.0, 10.5, 7.0, 7.0 Hz, H27), 5.86 (1H, d, J = 12.0 Hz, H17),


5.84 (1H, d, J = 12.0 Hz, H18), 5.70 (1H, ddd, J = 11.5, 3.0, 3.0 Hz, H6), 5.53 (1H,


m, H7), 5.51 (1H, d, J = 13.0 Hz, H21), 5.46 (1H, d, J = 13.0 Hz, H22),


5.24 (2H, s, NAP), 5.20 (1H, d, J = 12.0 Hz, NAP), 5.13 (1H, dd, J = 17.0, 2.5 Hz,


H26′), 5.06 (1H, dd, J = 10.0, 2.5 Hz, H26′), 5.05 (1H, dd, J = 10.5, 2.0 Hz,


H27′), 5.04 (1H, d, J = 12.0 Hz, NAP), 5.01 (1H, dd, J = 17.0, 2.5 Hz, H27′),


4.86 (1H, d, J = 12.5 Hz, NAP), 4.83 (1H, d, J = 12.5 Hz, NAP), 4.81 (1H, d,


J = 12.5 Hz, NAP), 4.62 (1H, d, J = 12.5 Hz, NAP), 4.54 (1H, m, H5),


4.51 (2H, s, NAP), 4.33 (2H, s, NAP), 4.20 (1H, m, H2), 4.18 (1H, d, J = 9.0 Hz,


H19), 4.17 (1H, m, H44), 4.10 (1H, m, H30), 4.08 (1H, m, H54), 4.06 (1H, m,


H55), 3.99 (1H, d, J = 9.5 Hz, H48), 3.94 (1H, d, J = 9.0 Hz, H20), 3.89 (1H,


dd, J = 7.0, 7.0 Hz, H29), 3.83 (1H, d, J = 9.5 Hz, H16), 3.81 (1H, m, H55),


3.80 (1H, dd, J = 9.5, 9.5 Hz, H49), 3.77 (1H, d, J = 9.0 Hz, H23), 3.70 (1H,


dd, J = 9.0, 3.5 Hz, H11), 3.69 (1H, dd, J = 10.5, 4.0 Hz, H1), 3.66 (1H, d, J = 3.5 Hz,


H47), 3.57 (1H, dd, J = 8.5, 4.5 Hz, H34), 3.54 (1H, m, H24),


3.52 (1H, dd, J = 10.5, 4.0 Hz, H1), 3.52 (1H, m, H32), 3.51 (1H, m, H37),


3.48 (1H, dd, J = 9.0, 9.0 Hz, H10), 3.29 (1H, ddd, J = 9.0, 9.0, 4.0 Hz, H9),


3.16 (1H, ddd, J = 11.5, 9.5, 4.5 Hz, H15), 3.14 (1H, dd, J = 9.0, 9.0 Hz, H12),


3.11 (1H, m, H41), 3.06 (1H, dd, J = 8.5, 4.5 Hz, H45), 2.98 (1H, m, H36),


2.96 (1H, m, H42), 2.93 (1H, m, H13), 2.58 (1H, ddd, J = 16.0, 9.0, 4.5 Hz,


H8), 2.55 (1H, m, H46), 2.53 (1H, m, H25), 2.41 (1H, ddd, J = 11.5, 4.5, 4.5 Hz,


H43), 2.35 (1H, ddd, J = 11.5, 4.5, 4.5 Hz, H14), 2.29 (1H, m, H8),


2.27 (1H, m, H25), 2.24 (1H, m, H53), 2.23 (1H, m, H53), 2.22 (1H, m, H28),


2.14 (1H, m, H31), 2.13 (1H, m, H35), 2.07 (1H, m, H38), 2.06 (1H, m, H40),


2.04 (1H, m, H50), 2.02 (1H, m, H28), 1.96 (1H, m, H31), 1.93 (1H, m, H35),


1.90 (1H, m, H39), 1.73 (1H, ddd, J = 11.5, 11.5, 11.5 Hz, H43), 1.71 (1H, ddd, J = 1.5,


11.5, 11.5 Hz, H14), 1.65 (1H, m, H40), 1.59 (1H, m, H38), 1.56 (1H,


m, H51), 1.27 (3H, d, J = 7.0 Hz, Me59), 1.25 (3H, s, Me56), 1.23 (3H, d, J = 7.5 Hz,


Me60), 1.22 (3H, d, J = 6.5 Hz, Me58), 0.96 (3H, d, J = 6.0 Hz,


Me57);


13C NMR (125 MHz, C6D6) δ 137.6, 137.3, 136.9, 136.7, 136.5, 135.4, 135.2,


135.0, 134.4, 134.2, 134.1, 134.04, 134.01, 133.99, 133.98, 133.96, 133.95,


133.92, 133.59, 133.55, 133.53, 133.31, 131.5, 131.1, 130.8, 130.4, 129.3,


129.2, 128.47, 128.42, 128.35, 128.2, 126.9, 126.66, 126.65, 126.58, 126.56,


126.54, 126.48, 126.45, 126.34, 126.29, 126.24, 126.23, 126.21, 126.13,


126.07, 126.00, 125.94, 125.88, 125.7, 124.93, 124.88, 117.4, 109.5, 87.4,


87.2, 85.6, 84.5, 83.8, 83.50, 83.46, 82.8, 82.2, 81.8, 81.2, 80.83, 80.77, 80.4,


79.4, 79.22, 79.18, 78.6, 76.8, 75.4, 74.9, 74.0, 73.9, 73.6, 73.51, 73.46, 72.84,


72.81, 72.5, 71.83, 71.75, 71.3, 71.1, 63.3, 62.4, 46.4, 43.3, 42.3, 41.4, 40.7,


40.3, 39.2, 38.5, 37.6, 36.3, 34.9, 34.4, 32.0, 27.7, 27.3, 25.4, 24.2, 22.0, 20.2,


16.4, 14.2, 14.0, 9.8;


MALDI-TOF MS, calcd. for C128H138NaO19 2001.9730 (M + Na+), found for


2001.9711









Synthesis of Compound 8





(PCy3)2Cl2Ru═CHPh (Grubbs catalyst, 0.2 mg, 0.24 μmol) is added to CH2Cl2 (1.0 mL, 0.7 nM) solution of frozen and de-aired compound 7 (1.3 mg, 0.66 μmol) and stirred at 40° C. for 4 hours. To this solution, Et3N (0.1 mL) is introduced and reaction is stopped, then concentrated and refined by a flush column, thus pentaene (1.0 mg, 0.51 μmol, 78%) of compound 8 is obtained. Features of compound 8 are shown in Table 8.







TABLE 8







[α]D25 −6.2 (c 0.10, CH2Cl2); IR (film) ν 2924, 2854, 1736, 1457, 1268, 1092 cm−1;


1H NMR (500 MHz, C6D6) δ 8.00-7.00 (42H, m, NAP × 6), 5.99 (1H, dd, J = 15.5,


3.5 Hz, H4), 5.95 (1H, dd, J = 15.5, 3.5 Hz, H3), 5.89 (1H, d, J = 13.0 Hz,


H18), 5.88 (1H, m, H26), 5.88 (1H, m, H27), 5.86 (1H, m H21), 5.78 (1H,


d, J = 13.0 Hz, H17), 5.69 (1H, ddd, J = 11.0, 3.0, 3.0 Hz, H6), 5.57 (1H, m,


H22), 5.53 (1H, m, H7), 5.26 (2H, s, NAP), 4.99 (1H, d, J = 12.5 Hz, NAP),


4.88 (1H, d, J = 12.5 Hz, NAP), 4.84 (1H, d, J = 12.5 Hz, NAP), 4.83 (1H, d,


J = 12.5 Hz, NAP), 4.81 (1H, d, J = 12.5 Hz, NAP), 4.61 (1H, d, J = 12.5 Hz,


NAP), 4.55 (1H, m, H5), 4.50 (2H, s, NAP), 4.34 (2H, s, NAP), 4.26 (1H, m,


H44), 4.19 (1H, m, H2), 4.10 (1H, m, H54), 4.07 (1H, d, J = 9.5 Hz, H48),


4.01 (1H, d, J = 10.0 Hz, H55), 4.00 (1H, d, J = 9.0 Hz, H20), 3.98 (1H, m,


H23), 3.92 (1H, m, H19), 3.84 (1H, d, J = 9.0 Hz, H16), 3.83 (1H, dd, J = 9.5,


9.5 Hz, H49), 3.81 (1H, dd, J = 10.0, 5.0 Hz, H55), 3.74 (1H, dd, J = 9.0, 3.5 Hz,


H11), 3.72 (1H, dd, J = 6.5, 6.5 Hz, H30), 3.67 (1H, dd, J = 10.0, 7.0 Hz,


H1), 3.67 (1H, d, J = 3.5 Hz, H47), 3.59 (1H, dd, J = 9.0, 9.0 Hz, H10),


3.53 (1H, m, H32), 3.52 (1H, dd, J = 10.0, 4.0 Hz, H1), 3.51 (1H, m, H29),


3.49 (1H, m, H24), 3.46 (1H, m, H37), 3.33 (1H, ddd, J = 9.0, 9.0, 4.0 Hz, H9),


3.27 (1H, dd, J = 9.0, 9.0 Hz, H12), 3.17 (1H, ddd, J = 11.5, 9.0, 4.0 Hz, H15),


3.13 (1H, m, H41), 3.10 (1H, dd, J = 9.0, 4.5 Hz, H45), 3.05 (1H, m, H42),


3.03 (1H, m, H34), 2.96 (1H, m, H13), 2.94 (1H, m, H36), 2.87 (1H, m, H25),


2.86 (1H, m, H28), 2.61 (1H, ddd, J = 16.0, 8.0, 4.0 Hz, H8), 2.58 (1H, m,


H25), 2.58 (1H, m, H28), 2.56 (1H, m, H46), 2.48 (1H, ddd, J = 12.0, 5.0, 5.0 Hz,


H43), 2.39 (1H, m, H31), 2.34 (1H, m, H14), 2.33 (1H, m, H8), 2.24 (1H,


m, H53), 2.23 (1H, m, H53), 2.21 (1H, m, H31), 2.14 (1H, m, H50), 2.09 (1H,


m, H40), 2.06 (1H, m, H35), 2.02 (1H, m, H38), 1.87 (1H, m, H39), 1.86 (1H,


m, H35), 1.79 (1H, ddd, J = 12.0, 12.0, 12.0 Hz, H43), 1.72 (1H, ddd, J = 11.5,


11.5, 11.5 Hz, H14), 1.66 (1H, m, H40), 1.60 (1H, m, H38), 1.56 (1H, m,


H51), 1.36 (3H, s, Me56), 1.29 (3H, d, J = 6.5 Hz, Me59), 1.17 (3H, d, J = 7.5 Hz,


Me58), 1.16 (3H, d, J = 7.0 Hz, Me60), 0.98 (3H, d, J = 7.5 Hz, Me57);


MALDI-TOF MS, calcd. for C126H134NaO19 1973.9421 (M + Na+), found for


1973.9417









Synthesis of Aimed Compound CTX1B.





DDQ (1.6 mg, 6.9 μmol) is added to CH2Cl2 (100 μL)-water (100 μL) solution of compound 8 (450 μg, 0.23 μmol) and stirred at room temperature for 45 minutes. Na2S2O3 aqueous solution is added and reaction is stopped, and diluted by ethyl acetate and saturated NaHCO3 aqueous solution. Water phase is extracted by ethyl acetate for 5 times and combined organic layer is washed by saturated brine, then solvent is concentrated. Obtained mixture is refined by HPLC and compound E is obtained. Hydrochloric acid (1N. 50 μL) is added to methanol (200 μL) solution of compound E is added and stirred at room temperature for 30 minutes. Saturated NaHCO3 aqueous solution is added to this solution and reaction is stopped, then concentrated. This mixture is diluted by water and ethyl acetate for 5 times, and combined organic layer is concentrated. Crude CTX1B is refined by HPLC and CTX1B (108 μL mg, 0.097 μmol, 42%) is obtained. Features of synthesized CTX1B are shown in Table 9.







TABLE 9







1H NMR (500 MHz, C6D5N) δ 7.30 (1H, d, J = 4.0 Hz, OH11), 6.75 (1H, d, J = 3.5 Hz,


OH47), 6.63 (1H, d, J = 4.0 Hz, OH2), 6.52 (1H, d, J = 4.0 Hz,


OH54), 6.39 (1H, t, J = 5.0 Hz, OH1), 6.38 (1H, dd, J = 15..0, 3.0 Hz, H4),


6.35 (1H, dd, J = 15.0, 3.0 Hz, H3), 6.03 (1H, d, J = 13.0 Hz,, H22), 5.97 (1H,


m, H26), 5.97 (1H, m, H27), 5.91 (1H, ddd, J = 11.5, 3.0, 3.0 Hz, H6),


5.89 (1H, d, J = 12.5 Hz, H18), 5.53 (1H, dddd, J = 11.5, 8.0, 3.0, 3.0 Hz, H7),


5.74 (1H, d, J = 12.5 Hz, H17), 5.67 (1H, m H21), 5.26 (1H, m, OH54),


4.86 (1H, m, H5), 4.86 (1H, m, H54), 4.69 (1H, m, H2), 4.48 (1H, ddd, J = 12.0,


10.0, 5.0 Hz, H44), 4.22 (1H, dd, J = 3.5, 3.5 Hz, H47), 4.21 (1H, m, H20),


4.19 (1H, m, H55), 4.17 (1H, m, H55), 4.16 (1H, m, H32), 4.10 (1H, ddd, J = 9.0,


9.0, 4.0 Hz, H11), 4.07 (1H, d, J = 10.0 Hz, H48), 4.05 (1H, m, H19),


4.03 (1H, m, H23), 4.02 (1H, d, J = 10.0 Hz, H16), 4.00 (1H, ddd, J = 10.0,


5.0, 5.0 Hz, H1), 3.98 (1H, dd, J = 10.0, 5.0, 5.0 Hz, H1), 3.97 (1H, dd, J = 10.0,


10.0 Hz, H49), 3.78 (1H, m, H29), 3.76 (1H, dd, J = 9.0, 9.0 Hz, H10),


3.61 (1H, m, H24), 3.57 (1H, m, H30), 3.54 (1H, m, H15), 3.50 (1H, m, H37),


3.49 (1H, ddd, J = 9.0, 9.0, 4.0 Hz, H9), 3.44 (1H, dd, J = 9.0, 9.0 Hz, H12),


3.35 (1H, ddd, J = 12.0, 9.0, 4.5 Hz, H13), 3.34 (1H, m, H36), 3.34 (1H, m,


H42), 3.32 (1H, dd, J = 12.0, 4.5 Hz, H34), 3.22 (1H, ddd, J = 10.0, 10.0, 3.0 Hz,


H41), 3.21 (1H, dd, J = 10.0, 5.0 Hz, H45), 2.94 (1H, m, H25), 2.94 (1H,


m, H28), 2.73 (1H, ddd, J = 16.0, 8.0, 4.0 Hz, H8), 2.60 (1H, m, H31),


2.59 (1H, m, H43), 2.59 (1H, m, H46), 2.57 (1H, m, H31), 2.56 (1H, m, H14),


2.53 (1H, m, H8), 2.40 (1H, dd, J = 9.0, 6.5 Hz, H53), 2.36 (1H, m, H28), 2.34 (1H,


dd, J = 9.0, 3.5 Hz, H53), 2.26 (1H, ddd, J = 12.0, 4.5, 4.5 Hz, H35), 2.20 (1H,


m, H25), 2.04 (1H, m, H40), 2.00 (1H, m, H50), 1.92 (1H, ddd, J = 12.0, 12.0,


12.0 Hz, H35), 1.90 (1H, m, H39), 1.85 (1H, ddd, J = 12.0, 12.0, 12.0 Hz,


H14), 1.83 (1H, m, H38), 1.78 (1H, ddd, J = 12.0, 12.0, 12.0 Hz, H43),


1.73 (1H, m, H40), 1.67 (1H, m, H51), 1.54 (1H, m, H38), 1.38 (3H, s, Me56),


1.32 (3H, d, J = 7.0 Hz, Me59), 1.31 (3H, d, J = 6.0 Hz, Me58), 1.23 (3H, d, J = 6.5 Hz,


Me60), 0.93 (3H, d, J = 7.0 Hz, Me57);


MALDI-TOF MS, calcd. for C60H86O19 1133.5661 (M + Na+), found for


1133.5583









Illustration of Shortened Marks in this Application

    AIBN α,α′-azobis(isobutyronitrile)
    Cy cyclohexyl
    DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
    DIBAL diisobutylaluminumhydride
    DMSO dimethylsulfoxide
    DTBMP 2,6-di-t-butyl-4-methylpyridine
    Grubbs catalyst benzylidene-bis(tricyclohexylphosphine)dichlororuthenium
    HPLC high performance liquid chromatography
    Me Methanol
    NaHMDS sodium bis(trimethylsilyl)amide
    NAP 2-naphthylmethyl
    Ph phenyl
    TBAF tetrabutylammonium fluoride
    Tf trifluoromethanesulfonyl
    THF tetrahydrofuran
    TMS trimethylsilyl
    TIPS triisopropylsilyl


INDUSTRIAL APPLICABILITY
The present invention makes possible to provide necessary amount of said compound for progressing bioscience research or development of method for detection of ciguatera poisoned fish, and is useful for industrial use applicable as a standard sample for ciguatera food-poisoning happened in all over the world.

## Claims

1. A method for preparation of CTX1B including the following steps:



oxidizing the double bond of compound A




by osmium tetra oxide to form a diol derivative of compound A, and transforming the diol to aldehyde by oxidative cleavage using sodium periodate, then reducing the aldehyde to alcohol using sodium borohydride and obtaining compound 1;




transforming the alcohol of compound 1 to compound 2 using diphenyldisulfide•tributylphosphine;




transforming said compound 2 using α-chlorosulphide to synthesize compound B;




joining under presence of DTBMP said compound B to ABCDE ring segments of compound C as O,S-acetal using silver triflate and forming compound 3;




removing TIPS group of said compound 3 using TBAF and forming compound 4;




joining pentafluorophenylpropiolate to alcohol of said compound 4 using trimethylphosphine and forming compound 5;




carrying out radical cyclization reaction on said compound 5 by treating with AIBN and tintributyl hydride and forming G ring part, so that said compound 5 transforms to carboxylic acid of compound D;





transforming to methyl ester by acting trimethylsilyldiazomethane and forming compound 6;



forming compound 7 by reducing methyl ester of said compound 6 by diisobutylaluminum hydrate under lower temperature condition, then transforming to olefin by Wittig reaction;




forming compound 8 by forming F ring part by carrying out ring closure methathesis reaction using a Grubbs catalyst to said compound 7;




synthesizing compound E, 1,2-diol of A ring side chain of which is protected by naphthylacetal, by oxidizing 6 NAP groups using DDQ and removing 5 NAP groups; and




carrying out acid treatment on said compound E and obtaining CTX1B,
wherein, in compounds A, B, C, D, E, CTX1B and compounds 1-8, NAP is 2-naphthylmethyl group, Me is methyl group, TIPS is triisopropylsilyl group, Ph is phenyl group, wherein DTBMP is 2,6-di-t-butyl-4-methylpyridine, TBAF is tetrabutylammonium fluoride, AIBN is α, α′-azobis(isobutyronitrile), and DDQ is 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

2. A novel compound represented by compound 1 to be used for preparation of CTX1B

3. A novel compound represented by compound 2 to be used for preparation of CTX1B of claim 1

4. A novel compound represented by compound 3 to be used for preparation of CTX1B

5. A novel compound represented by compound 4 to be used for preparation of CTX1B

6. A novel compound represented by compound 5 to be used for preparation of CTX1B

7. A novel compound represented by compound 6 to be used for preparation of CTX1B

8. A novel compound represented by compound 7 to be used for preparation of CTX1B

9. A novel compound represented by compound 8 to be used for preparation of CTX1B